



RULES FOR PRICING OF GENERICS

The G-BA does not conduct early benefit assessments for generic products. Therefore, there are no subsequent price negotiations.



**Gemeinsamer
Bundesausschuss**



Instead, manufacturers
are free to set the price
of their generic drugs,
based on the
competitive market.



However, the reference
price dictates the
maximum price that SHI
funds will pay for the
generic.



If the manufacturer priced their generic drug higher than the reference price, there are two options.



Either, the patients will have
to cover the price difference,
or



Pharmacies will switch to a different product that is therapeutically equivalent, but does not require a payment by the patient.



Therefore,
manufacturers tend to
not price their generic
product (much) higher
than the reference
price.



Want to find out more?

Get In Touch



anja@anjapownell.com



germanmarketaccesssimplified.com

or get my **Free Guide to German HTA system**

A detailed guide to the 10 most commonly asked questions regarding early benefit assessments

